BRAF and breast cancer: Recently, SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor which preferentially affects cell survival of BRCA2-deficient breast cancer cells, as well as also induces apoptosis and cell cycle arrest in BRAF-mutant or non-BRAF-mutant melanoma [10–12].